All ‐cause mortality versus cancer‐specific mortality as outcome in cancer screening trials: A review and modeling study

ConclusionCancer screening trials are able to demonstrate a significant reduction in all ‐cause mortality due to screening, but require very large sample sizes. Depending on the cancer, 40 000‐600 000 participants per arm are needed to demonstrate a significant reduction. The reduction in all‐cause mortality can only be detected between specific years of follow‐up, more limite d than the timeframe to detect a reduction in cancer‐specific mortality.

Source: Cancer Medicine - August 17, 2019 Category: Cancer & Oncology Authors: Eveline A. M. Heijnsdijk, Marcell Csan ádi, Andrea Gini, Kevin ten Haaf, Rita Bendes, Ahti Anttila, Carlo Senore, Harry J. de Koning Tags: ORIGINAL RESEARCH Source Type: research